BAUDETTE, Minn. , Feb. 12, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL. The current annual market for this product is approximately $29 million , according to IQVIA. This launch represents ANI’s third generic product introduction in 2020. Art
February 12, 2020
· 3 min read